All Stories

  1. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors

    Article • Alimentary Pharmacology & Therapeutics, May 2017, Wiley

    Mark Ward

  2. Editorial: variability in adalimumab trough and peak serum concentrations - authors’ reply

    Article • Alimentary Pharmacology & Therapeutics, May 2017, Wiley

    Mark Ward

  3. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease

    Article • Alimentary Pharmacology & Therapeutics, February 2017, Wiley

    Dr Gennaro Jim Rosella, Phoebe Thwaites, Mark Ward

  4. escalation to weekly dosing in adalimumab-treated patients with active ulcerative colitis

    Article • Alimentary Pharmacology & Therapeutics, August 2014, Wiley

    Mark Ward